                               SEQUENCE LISTING

<110> LANTHIOPEP B.V.
 
<120> ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE 
      TREATMENT OF CANCER

<130> MS278/EP-PROV

<140>
<141>

<160> 8     

<170> PatentIn version 3.5

<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Tyr" or "Asp" or "Ile" or "pGlu"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Abu" 

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Abu" 

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 1
Lys Asp Arg Val Ala Ile His Ala 
1               5               


<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Abu" 

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Abu" 

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 2
Lys Asp Arg Val Ala Ile His Ala 
1               5               


<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Abu" 

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Abu" 

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 3
Asp Asp Arg Val Ala Ile His Ala 
1               5               


<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Abu" 

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Abu" 

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 4
Tyr Asp Arg Val Ala Ile His Ala 
1               5               


<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Abu" 

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Abu" 

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 5
Ile Asp Arg Val Ala Ile His Ala 
1               5               


<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Abu" 

<220>
<221> VARIANT
<222> (8)..(8)
<223> /replace="Abu" 

<220>
<221> SITE
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 6
Asn Asp Arg Val Ala Ile His Ala 
1               5               


<210> 7
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 7
Asp Arg Val Tyr Ile His Pro Phe 
1               5               


<210> 8
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 8
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Leu Tyr Arg Ser Pro 
1               5                   10                  15      


Ala Met Pro Glu Asn Leu 
            20          


